Business
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
CHICAGO, July 28, 2025--MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/d561e2aa7f6a46093d08df0957357e3e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p6cvdhj6Z.w.QMeCSixHYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d561e2aa7f6a46093d08df0957357e3e","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/G8b3iYnmMQ0vvsPr1vZGMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d561e2aa7f6a46093d08df0957357e3e","width":1000,"height":380}},"lazy":false},{"type":"text","content":"Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment market","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"CHICAGO, July 28, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.","length":615,"tagName":"p"},{"type":"text","content":"Ateganosine is a first-in-class small molecule that compromises telomere structure and function in cancer cells, leading to rapid tumor cell elimination and specific immune memory. Through telomerase-mediated action, ateganosine reverses intrinsic or acquired resistance to immune checkpoint inhibitors (ICIs).","length":310,"tagName":"p"},{"type":"text","content":""FDA’s Fast Track Designation recognizes ateganosine’s potential as a new therapeutic paradigm in cancer treatment science. Ateganosine is the first and only anticancer treatment of its kind that we are aware of in clinical development,&q...